VIP vs PNC27
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Vasoactive Intestinal Peptide, Aviptadil
A naturally occurring peptide with immunomodulatory and anti-inflammatory effects. Being studied for ARDS, pulmonary hypertension, and autoimmune conditions.
Also: PNC-27, p53-HDM2 Disruptor Peptide
A chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. Selectively kills cancer cells by binding to HDM-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
- VIP has stronger research evidence (Human Trials) compared to PNC27 (Animal Studies).
Detailed Comparison
| Attribute | VIP | PNC27 |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | VIP binds to VPAC1 and VPAC2 receptors, triggering anti-inflammatory cascades. It relaxes smooth muscle, vasodilates, inhibits pro-inflammatory cytokines, and promotes regulatory T-cell function. Has broad immunomodulatory effects. | PNC27 contains two functional domains: residues 12-26 of the p53 HDM-2 binding domain on the N-terminus, and a membrane residency peptide (MRP/penetratin) on the C-terminus. Cancer cells uniquely express HDM-2 on their plasma membranes, while normal cells do not. PNC27 binds to this membrane-bound HDM-2, adopts an alpha-helical conformation similar to p53, and induces transmembrane pore formation. This causes extrusion of intracellular contents and rapid necrotic cell death. The peptide also enters cancer cells and disrupts mitochondrial membranes. Importantly, this mechanism is independent of intracellular p53 status - effective even in p53-null cancers. |
| Common Dosing | 50-100 mcg intranasal daily 1-2x daily, intranasal | No human dose - research compound only Not applicable - no human use |
| Administration | IV infusion, inhaled, or intranasal | IV injection in animal studies - not for human use |
| Typical Duration | Variable by indication | Research protocols only - no human use data |
| Best Time to Take | Morning or as directed | Per research protocol |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Clinical trials for COVID-19 ARDS showed promising results. Research demonstrates benefits in pulmonary arterial hypertension. Studies show potential for autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease. | Extensive in vitro research demonstrates PNC27 selectively kills multiple cancer cell types including breast (MCF-7), pancreatic (MIA-PaCa-2), cervical (HeLa, SW756), ovarian (OVCAR-3, OV-90), colon, lung, and leukemia (K562, U937, HL-60) cell lines. Effective concentration: 0.1-0.2 mg/mL kills most cancer cells. At 0.3 mg/mL, nearly 100% of K562 leukemia cells were killed. Studies confirm no toxicity to normal cells including fibroblasts and leukocytes. Mechanism involves membrane pore formation and necrosis (not apoptosis). Research published in PNAS and multiple peer-reviewed journals. |
Frequently Asked Questions: VIP vs PNC27
What is the difference between VIP and PNC27?
VIP is a immune peptide that a naturally occurring peptide with immunomodulatory and anti-inflammatory effects. being studied for ards, pulmonary hypertension, and autoimmune conditions. PNC27 is a immune peptide that a chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. selectively kills cancer cells by binding to hdm-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected. The main differences lie in their mechanisms of action and clinical applications.
Which is better, VIP or PNC27?
Neither is universally "better" - the choice depends on your specific goals. VIP is typically used for immune purposes, while PNC27 is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can VIP and PNC27 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using VIP and PNC27 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of VIP and PNC27 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.